Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of epivotide nasal drops for perennial allergic rhinitis
CTR20221386Phase 2Active
- Sponsor
- Wuhan Yicheng Biotechnology
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of epivotide, sponsored by Wuhan Yicheng Biotechnology. Started Sep 2022; status: active.
02
Drugs
epivotide
Beyond the preview
Go deeper on CTR20221386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221386.